ArticleScientific reports2026
Deciduous pulp stem cell-derived extracellular vesicles stimulate the proliferation of cartilage progenitor cells via extracellular signal-regulated protein kinase 1/2 activation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The developmental dysfunction of cartilage progenitor cells (CPCs) causes dwarfism. Radical therapies for dwarfism remain underdeveloped. Recently, the therapeutic benefits of extracellular vesicles (EVs) released from human exfoliated deciduous tooth-derived stem cells (SHED) have been investigated for their potential to restore disease-target cells. However, the effects of EVs on human CPCs for the treatment of dwarfism remain unclear. We investigated the impact of EVs on cell proliferation, telomerase activity, telomerase reverse transcriptase (TERT) expression, cell cycle, and extracellular signal-regulated protein kinase 1/2 (ERK1/2) levels in human CPCs and in our established osteogenesis imperfecta (OI)-specific SHED (OI-SHED). EVs enhanced the proliferation and G1/S phase transition of CPCs, which was associated with increased TERT expression and telomerase activity. However, RNase-preconditioned EVs did not attenuate the efficacy of EVs in CPCs. ERK1/2 inhibitor tests demonstrated that CPCs exhibited suppressed proliferation, telomerase activity, and G1/S phase progression. EV-transferring CD29 induced ERK1/2 phosphorylation in CPCs, subsequently activating telomerase activity to induce proliferation. Interestingly, EV stimulation restored the reduction in cell proliferation, cell cycle progression, phosphorylated ERK1/2 levels, and TERT expression in OI-SHED. In conclusion, the present findings provide new insights into ERK1/2-mediated proliferation of human CPCs using EVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.